Tiger Brokers

  • Markets
    • Quotes
    • 24/7 News
  • Products
    • Cash Boost Account
    • Options
    • China A-shares
    • HK Stocks
    • Fixed Coupon Notes
    • US Stocks
    • ETFs
    • Funds
    • US Treasury
    • Singapore Stocks
    • Futures
    • Tiger BOSS Debit Card
    • Tiger Vault
  • Features
    • Auto-invest
    • Invest with CPF/SRS
    • Learn
    • US Fractional Shares
  • TigerAI
  • Pricing
    • Prime
      • Stocks & ETFs
      • Options, Warrants & CBBCs
      • Futures
      • Bonds
      • Fund Mall
    • Cash Boost
      • Stocks & ETFs
    • Financing Interest Rates
  • Promotions
  • Help
    • Account Operations
      • How to Open an Account?
      • Account Opening Documents
      • Account Types Available
    • Transfer & Pay
      • Account Funding
      • DDA Fast Deposit
      • Funds Withdrawal
      • Shares Transfer-in
      • Shares Transfer-out
      • Currency Conversion
    • Products & Trading
      • Products Available
      • Order Types
      • Trading Rules
      • Declaration
    • Margin Trading & Short Selling
      • Margin & Leverage
      • Risk Management
      • Short Selling Risk
    • Fund Mall
      • Open a fund account and transaction
    • Cash Boost Account
      • Cash Boost Account FAQ
      • How to Open Cash Boost Account
      • How to Contra Trade using Cash Boost Account
      • How to link your CDP Securities Account
    • Tiger Boss Debit Card
      • Frequently Asked Questions
      • Fees of the Debit card
      • How to Top-up
      • How to use my Debit card
    • Statement
      • Statement
      • Dividends
  • Institution
    • Tiger Fund Management
    • Institution Service
      • Wealth and asset manager
      • Proprietary trading institutions
      • Introducing brokers
      • Third-party service provider
    • Tiger Open Platform
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.62
+0.08005.19%
Post-market: 1.660.0400+2.47%19:51 EST
Volume:931.67K
Turnover:1.49M
Market Cap:196.02M
PE:-2.90
High:1.65
Open:1.56
Low:1.53
Close:1.54
52wk High:4.20
52wk Low:1.33
Shares:121.00M
Float Shares:71.11M
Volume Ratio:2.51
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5579
EPS(LYR):-1.1606
ROE:-131.71%
ROA:-79.11%
PB:2.69
PE(LYR):-1.40

Loading ...

OverviewCompanyNewsFilings

Inhibikase Therapeutics Strengthens Leadership Team With Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

THOMSON REUTERS
·
Aug 19

Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 15

Inhibikase Therapeutics Inc - to Initiate Phase 2B Study of Ikt-001 in Pah in H2 2025

THOMSON REUTERS
·
Aug 15

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

GlobeNewswire
·
Aug 15

Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
Aug 09

Inhibikase Therapeutics Inc. Concluded Annual Stockholder Meeting

Reuters
·
Jul 01

Ludwig Enterprises Inc. Appoints Garth Lees-Rolfe as New Independent Director

Reuters
·
Jun 26

BRIEF-Inhibikase Therapeutics files for mixed shelf of up to $300 mln

Reuters
·
Jun 21

Analyst Rate

Buy
Buy
75.00%
Hold
25.00%
Sell
0.00%

Corporate Actions

Financial Report Announcement
Nov 14, 2025 Post Market
Financial Report Announcement
Aug 14, 2025 Post Market
Financial Report Announcement
May 14, 2025 Post Market
Financial Report Announcement
Mar 27, 2025 Post Market
Financial Report Announcement
Nov 14, 2024 Pre-Market

Dividend History

no data

No relevant data is available

Valuation Analysis

-2.89
Current
-5.39
Sector Average
34.59%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-2.89
Maximum
-0.24
+1 STD
2.76
Minimum
-45.50
-1 STD
-13.54
Average
-5.39

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Trade Technology Pte. Ltd.
Email Address:
dpo@itiger.com
User Agreement|Privacy Policy

Copyright © Tiger Trade Technology Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.